With regulatory grounds broken, more big pharma companies are now scrambling to jump on the hot bus for cell and gene therapy, and Celgene’s push for complete acquisition of Juno Therpeutics at an offer price of $ 9 billion is a classic example of the trend. With a lead gene therapy candidate for relapsed or refractory aggressive B-cell non-Hodgkin lymphoma, Juno becomes a strategic fit for Celgene to cushion its fall from the impending patent expiry of its oncology blockbuster Revlimid. Takeda’s acquisition of TiGenix for its validated allogeneic expanded adipose-derived stem cell platform technology is another deal that signifies increasing industry momentum in the frontier field.
Biotech Startups in India – At the Cusp of Global Impact
Excerpts from the CII Sathguru publication released at the National Biotech Conclave, December 2017
Era 1.0: Laying a Strong Foundation for the Biotech Startup Ecosystem
- Rich ecosystem of more than 500 ventures, passionately advancing innovation to markets.
- Quantum leap in level of extramural funding programs such as SBIRI, BIPP and BIG – one of the most significant stimulants for the entrepreneurship wave
- Creation of platforms for convergent innovation appended by newer set of initiatives like start-up India, corpus funds, biotech parks, better defined regulatory policies have given necessary backbone for rapid growth
Era 2.0: Overview of the Current Landscape
- Ease of access to non-dilutive grants has prompted the rise of first generation entrepreneurs, to step out of secure jobs and take the entrepreneurial plunge.
- Evident geographical concentration and rise of regional clusters of excellence and biotech growth.
- Pronounced areas of innovation across devices and diagnostics and upstream drug discovery, addressing national needs.
- A parallel stream of nextgen innovations in genomics, regenerative medicine, AI & ML catering to global markets
Era 3.0: Recommendations for Triggering Global Impact
- Encouraging greater science sophistication in ventures to create globally benchmarkable science
- Leapfrogging Institutional Engagement in Translational Research for more market relevant research
- Addressing Glaring Void in Scale-up Funding: Aggregate investment required for developing assets in current pipeline until stage of commercialization is estimated to be USD 6.2 Billion.
- Creating Reward for Innovation and Fostering Market Maturity
- Improving ease of doing business by enhancing clarity on policy and regulations, creating a pro-IP perception in the global context, and making tax regime more globally competitive
Click here to download the white paper
SATHGURU IN THE NEWS
Quoted in Nature publication on “India’s commitment to science begins to pay off”
Patent to Pfizer could delay Indian vaccines for pneumonia
GST Impact on different Healthcare Sectors
Medical Buyer: Orthopedic Devices Market – At a Turning Point
- Critical care medical device – Opportunity assessment & India market entry strategy
- Specialty ophthalmic medical device – business plan for India operations
- Assessment of landscape – pharma (API and formulations) and innovation led ventures for a PE fund
- Sell side mandate – portfolio of complex generics (injectables & oral solids)
- Technology scout/buy-side mandate – portfolio of vaccines and specialty nutrition products
- Transaction Advisory – Series A investment in drug discovery venture from Swiss investment group
- SeriesA VC fund raising – Artificial Intelligence based digital health venture
- Cold Chain Technologies: Transforming Food Supply Chains
- Embracing Innovation, Driving Growth Across Healthcare Continuum – “Making in India”
- The Make in India Imperative – Position Paper on Regulatory and Policy Changes required for Sustained Competitiveness of the Indian Vaccine Industry
- Indian Orthopedic Devices Market A $2.4 Bn Opportunity
- Biosimilars – How can we realize the $ 240 Bn Opportunity